With additional laboratory studies, this association – observed over the last 15 years – has suggested that UA may actually be causative in some NASH patients. Recent studies have also shown that drugs that block UA production and/or accelerate its excretion can inhibit both development and progression of NASH. These results have prompted calls for clinical trials of potent hypouricemic drugs in NASH.
Relburn plans to test its unique drugs in clinical trials of patients afflicted with NASH in the setting of hyperuricemia.
Lanaspa M, et al.: Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 48:40732-44, 2012.
Sirota JC, et al.: Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome in the United States. Metabolism 62:392-99, 201. doi:
Choi Y-J, et al.: Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest 94;1114–25, 2014.
Kushiyama A, et al.: Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis. Mediators Inflam 2016.
Sun DQ, et al.: Serum uric acid: a new therapeutic target for nonalcoholic steatohepatitis. Expert Opin Ther Targets, 20:375-87, 2016. https://www.ncbi.nlm.nih.gov/pubmed/26419119
Zhou Z, et al.: Associations between serum uric acid and the remission of non-alcoholic fatty liver disease in Chinese males. PLos One 11/11/2016